Journal article
Metabolic karma-the atherogenic legacy of diabetes: The 2017 edwin bierman award lecture
ME Cooper, A El-Osta, TJ Allen, AMD Watson, MC Thomas, KAM Jandeleit-Dahm
Diabetes | AMER DIABETES ASSOC | Published : 2018
DOI: 10.2337/dbi18-0010
Abstract
Cardiovascular disease, despite all the recent advances in treatment of the various risk factors, remains the major cause of mortality in both type 1 and type 2 diabetes. Experimental models of diabetes-associated atherosclerosis, despite their limitations in recapitulating the human context, have assisted in the elucidation of molecular and cellular pathways implicated in the development and progression of macrovascular injury in diabetes. Our own studies have emphasized the role of oxidative stress and advanced glycation and identified potential targets for vasoprotective therapies in the setting of diabetes. Furthermore, it has been clearly shown that previous episodes of hyperglycemia pl..
View full abstractGrants
Funding Acknowledgements
M.E.C. has received grants and honoraria from companies making drugs currently used for management of diabetes and its complications, including Boehringer Ingelheim, Lilly, Novo Nordisk, AstraZeneca, and Bayer. M.C.T. has received honoraria for educational symposia conducted on behalf of pharmaceutical companies involved in the management of diabetes and its complications, including Boehringer Ingelheim, Lilly, AstraZeneca, Novartis, Merck Sharp & Dohme, Sanofi, Servier, and Mylan. No other potential conflicts of interest relevant to this article were reported.